Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Supernus Pharmaceuticals, Inc.
Study ID
NCT05518578
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • SPN-817 — DRUG
    oral capsule

Study Details

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

Key Dates

Start date
Feb 7, 2023
Status verified
Apr 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-Label Treatment
    0.25 mg to 4 mg SPN-817 taken orally twice daily

Primary Outcome Measure

Effects of SPN-817 on safety and tolerability [ Time Frame: 72 weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Green Leaf Clinical Trials, LLCJacksonvilleFlorida32258-
Visionary Investigators NetworkMiamiFlorida33133-

Find similar trials in Jacksonville, FL

By condition
Epilepsy
By specialty
NeurologyBrain disorders
By research site
Green Leaf Clinical Trials, LLC· Jacksonville, FLVisionary Investigators Network· Miami, FL

Related Studies